publishes research communications of outstanding significance and timeliness on topics at the interface of chemistry and biology, together with invited concise review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The journal continues to be a major forum for the first publication of new chemical entities prior to them entering clinical trials.The Journal welcomes papers on:the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targetsthe reporting of the discovery, design or optimization of potent new compounds or biological agentsthe analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental datathe reporting of "first-in-class" new therapeutic compoundsthe chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanismmethodological advances that are chemistry-based and which significantly impact on medicine or biologythe preparation and examination of biotherapeutics for the treatment of pathophysiological disease statesthe development of materials for specific therapeutic targetingManuscripts on phytochemistry, theoretical molecular dynamics and exclusively computational papers are out of scope. All manuscripts will be rigorously peer-reviewed by independent experts following an initial assessment by the Editors. Please note that BMCL is not suitable for straightforward reports of incremental advances. Above all the presentation of a rational basis and a sound underlying hypothesis for the work is of particular importance, whatever its exact field.

在化學與生物學的接口上發表具有突出意義和及時性的研究通訊，并邀請簡明的評論文章。該雜志發表了關于藥物化學、化學生物學和藥物發現與設計的實驗結果的報告，強調了這些領域新的和新出現的進展和概念。這本雜志的目的是促進人們更好地了解生命過程的分子水平、活生物體以及它們與化學試劑的相互作用。該雜志仍然是在新化學實體進入臨床試驗之前首次出版的主要論壇。該期刊歡迎發表以下論文：已建立或新的疾病靶點的藥物化學和相關生物學（包括靶點識別和確認）；發現、設計或優化有效新化合物或生物制劑的報告；利用體外和體內模型分析和討論與藥物設計和作用相關的結構-活性關系和藥理學問題，包括在與實驗數據密切相關時使用計算技術；“一流”新型治療化合物的報道；顯著提高生物機制知識的化學生物學或生物有機/生物無機化學；以化學為基礎，對醫學或生物學有重大影響的方法學進展；病理生理疾病狀態生物治療的制備與檢測；特定治療靶向材料的開發。有關植物化學、理論分子動力學和專門的計算論文的手稿超出范圍。所有手稿將由獨立專家在編輯初步評估后進行嚴格的同行評審。請注意，BMCL不適合直接報告增量預付款。最重要的是，無論工作的確切領域是什么，合理的基礎和合理的基本假設的提出都是特別重要的。